Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531.

CAS  Article  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/s0140-6736(18)32557-1.

Article  PubMed  Google Scholar 

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30. https://doi.org/10.1056/NEJMoa010187.

CAS  Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20. https://doi.org/10.1056/NEJMoa072252.

CAS  Article  PubMed  Google Scholar 

Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. https://doi.org/10.1016/s0140-6736(11)61873-4.

CAS  Article  PubMed  Google Scholar 

Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆). Ann Oncol. 2021;32:368–74. https://doi.org/10.1016/j.annonc.2020.11.017.

CAS  Article  PubMed  Google Scholar 

Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage iii gastric cancer: interim analysis of jaccro gc-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304. https://doi.org/10.1200/jco.18.01138.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase iii study of neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 versus surgery and adjuvant s-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13. https://doi.org/10.1200/jco.20.02914.

CAS  Article  PubMed  Google Scholar 

Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081–92. https://doi.org/10.1016/s1470-2045(21)00297-7.

CAS  Article  PubMed  Google Scholar 

Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy Trial. J Clin Oncol. 2016;34:2721–7. https://doi.org/10.1200/jco.2015.65.7692.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Mokadem I, Dijksterhuis WPM, van Putten M, et al. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;22:1263–73. https://doi.org/10.1007/s10120-019-00956-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Nakauchi M, Vos E, Tang LH, et al. Outcomes of neoadjuvant chemotherapy for clinical stages 2 and 3 gastric cancer patients: analysis of timing and site of recurrence. Ann Surg Oncol. 2021;28:4829–38. https://doi.org/10.1245/s10434-021-09624-5.

Article  PubMed  Google Scholar 

Ikoma N, Chen HC, Wang X, et al. Patterns of Initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679–87. https://doi.org/10.1245/s10434-017-5838-y.

Article  PubMed  Google Scholar 

Kim HD, Lee JS, Yook JH, et al. Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. Gastric Cancer. 2021. https://doi.org/10.1007/s10120-021-01243-z.

Article  PubMed  PubMed Central  Google Scholar 

Kim JW, Shin SS, Heo SH, et al. Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. Eur Radiol. 2012;22:654–62. https://doi.org/10.1007/s00330-011-2283-3.

Article  PubMed  Google Scholar 

Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49. https://doi.org/10.1093/annonc/mdw350.

CAS  Article  PubMed  Google Scholar 

Ganeshalingam S, Koh DM. Nodal staging. Cancer Imaging. 2009;9:104–11. https://doi.org/10.1102/1470-7330.2009.0017.

Article  PubMed  PubMed Central  Google Scholar 

Young JJ, Pahwa A, Patel M, et al. Ligaments and lymphatic pathways in gastric adenocarcinoma. Radiographics. 2019;39:668–89. https://doi.org/10.1148/rg.2019180113.

Article  PubMed  Google Scholar 

Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934–9. https://doi.org/10.1097/SLA.0b013e318216f449.

Article  PubMed  Google Scholar 

Li N, Wang X, Tang Y, et al. Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. Chin J Cancer Res. 2021;33:447–56. https://doi.org/10.21147/j.issn.1000-9604.2021.04.02.

Article  PubMed  PubMed Central  Google Scholar 

Ohashi M, Morita S, Fukagawa T, et al. Evaluation of 64-channel contrast-enhanced multi-detector row computed tomography for preoperative n staging in ct2-4 gastric carcinoma. World J Surg. 2016;40:165–71. https://doi.org/10.1007/s00268-015-3318-8.

Article  PubMed  Google Scholar 

Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21:68–73. https://doi.org/10.1007/s10120-017-0701-1.

Article  PubMed  Google Scholar 

Kemi N, Eskuri M, Herva A, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 2018;119:435–9. https://doi.org/10.1038/s41416-018-0202-y.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kunisaki C, Makino H, Kimura J, et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery. 2010;147:204–11. https://doi.org/10.1016/j.surg.2009.08.012.

Article  PubMed  Google Scholar 

Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18. https://doi.org/10.1016/s1470-2045(15)00553-7.

CAS  Article  PubMed  Google Scholar 

Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33. https://doi.org/10.1200/jco.2011.36.7136.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Reim D, Gertler R, Novotny A, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108–18. https://doi.org/10.1245/s10434-011-2147-8.

Article  PubMed  Google Scholar 

Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708. https://doi.org/10.1016/s1470-2045(16)30531-9.

CAS  Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Gastric Cancer (version 2.2022). 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 02 Aug 2022.

Cardoso R, Coburn N, Seevaratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S19-26. https://doi.org/10.1007/s10120-011-0115-4.

Article  PubMed  Google Scholar 

Choi JI, Joo I, Lee JM. State-of-the-art preoperative staging of gastric cancer by MDCT and magnetic resonance imaging. World J Gastroenterol. 2014;20:4546–57. https://doi.org/10.3748/wjg.v20.i16.4546.

Article  PubMed  PubMed Central  Google Scholar 

Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol. 2010;25:512–8. https://doi.org/10.1111/j.1440-1746.2009.06106.x.

Article  PubMed  Google Scholar 

Cimavilla-Roman M, de-la Serna-Higuera C, Loza-Vargas A, et al. Endoscopic ultrasound versus multidetector computed tomography in preoperative gastric cancer staging. Rev Esp Enferm Dig. 2017;109:761–7. https://doi.org/10.17235/reed.2017.4638/2016.

Article  PubMed  Google Scholar